Farmakologian ja toksikologian laitos
Department of Pharmacology and Toxicology

Julkaisut 2005
Publications 2005

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.


1 Airaksinen AJ et al. Synthesis and biological evaluation of 6/7-exo-methyl-3beta-(4-iodo)phenyltropane-2beta-carboxylic acid methyl esters.
2 Birioukova LM et al. Distribution of D1-like and D2-like dopamine receptors in the brain of genetic epileptic WAG/Rij rats.
3 Boghossian S et al. Suppression of fat deposition for the life time with gene therapy.
4 Forsberg M. Comparison of Pharmacokinetics and Pharmacodynamics of Catechol-O-Methyltransferase (COMT) Inhibitors: Non-Clinical and Safety Aspects.
5 Forsberg MM et al. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
6 Hartikainen S et al. Serotoniinisyndrooma: iäkästä miestä hikoiluttaa, ahdistaa ja tärisyttää.
7 Helin-Salmivaara A et al. Onko koksibien käyttö suositusten mukaista?
8 Helin-Salmivaara A et al. Frequent prescribing of drugs with potential gastrointestinal toxicity among continuous users of non-steroidal anti-inflammatory drugs.
9 Husgafvel-Pursiainen K et al. Special issue: The proceedings of the 10th International Congress of Toxicology, Tampere, Finland, July 11-15, 2004. Living in a safe chemical world.
10 Huupponen R. Glargiini-insuliinin käyttö lisääntyy - näyttö hyödystä?
11 Huupponen R. Lihavuuden hoidossa käytettävät lääkkeet.
12 Idänpään-Heikkilä JE et al. Mikä neuvoksi koksibikohun keskellä?
13 Jarho EM et al. Dicarboxylic acid azacycle L-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.
14 Jula A et al. Effects of diet and simvastatin on fatty acid composition in hypercholesterolemic men. A randomized controlled trial.
15 Klaukka T et al. Tulehduskipulääkkeet tarkastelussa.
16 Klaukka T et al. Simvastatiini sopii lipidihoidon peruslääkkeeksi.
17 Klaukka T et al. Koksibien käyttö jatkoi kasvuaan vuoden 2004 lopulla.
18 Klaukka T et al. Lääkekustannusten jyrkän kasvun taustatekijät vuosina 2000-2004.
19 Kokki H. Safe and effective spinal anaesthesia for children.
20 Kokki H et al. Oxycodone vs placebo in children with undifferentiated abdominal pain. A randomized, double-blind clinical trial of the effect of analgesia on diagnostic accuracy.
21 Kokki H et al. High success rate and low incidence of headache and neurological symptoms with two spinal needle designs in children.
22 Kokki H et al. Isobaric ropivacaine 5 mg/mL for spinal anesthesia in children.
23 Koponen E et al. Enhanced BDNF signaling is associated with an antidepressant-like behavioral response and changes in brain monoamines.
24 Korhonen LE et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors .
25 Kähkönen S et al. Serotonergic modulation of mismatch negativity.
26 Laitinen K. Mitä hormonaalisesta ehkäisystä kysytään useimmiten?
27 Laitinen K. Mitä tietoa PKV- ja huumausaineita sisältävien lääkkeiden käyttäjät kaipaavat?
28 Laitinen K, Annola K. Mitä lääkkeiden käyttäjät kysyvät haittavaikutuksista?
29 Lampela H et al. Charles Bonnet´n syndrooma - näkövammaisten näköharhat.
30 Laukkanen A et al. Ihon okasolusyöpä ja sen esiasteet.
31 Lecklin A et al. Perigestational suppression of weight gain with central leptin gene therapy results in lower weight F1 generation.
32 Liesivuori J. Ammonia. The Nordic Expert Group for Criteria Documentation of Health Risks from Chemicals. 137.
33 Lintula H et al. A diagnostic score for children with suspected appendicitis.
34 MacDonald E, Saarti J. Evaluation of a web-based course teaching information literacy to third year pharmacy students in the University of Kuopio, Finland.
35 Manakova S. Studies on the Mechanisms of 6-OHDA Toxicity in Neuronal and Non-neuronal Cells.
36 Manakova S et al. Failure of FK506 (tacrolimus) to alleviate apomorphine-induced circling in rat Parkinson model in spite of some cytoprotective effects in SH-SY5Y dopaminergic cells.
37 Midzyanovskaya I et al. Dual effect of pyrilamine on absence seizures in WAG/Rij rats.
38 Midzyanovskaya IS et al. Convulsive and nonconvulsive epilepsy in rats: effects on behavioral response to novelty stress.
39 Mykkänen H et al. Fecal and urinary excretion of aflatoxin B1 metabolites (AFQ1, AFM1 and AFB-N7-guanine) in young Chinese males.
40 Myllynen P et al. Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs.
41 Nikanne E et al. Celecoxib and ketoprofen for pain management during tonsillectomy: A placebo-controlled clinical trial.
42 Paija O et al. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
43 Pelkonen O, Raunio H. In vitro screening of drug metabolism during drug development: can we trust the predictions?
44 Pelkonen O et al. Prediction of drug metabolism and interactions on the basis of in vitro investigations.
45 Puncuh F et al. Spinal anaesthesia in paediatric patients.
46 Rahnasto M et al. Quantitative structure - activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
47 Raunio H. Merkittävimmät yhteisvaikutuksia aiheuttavat lääkkeet - kymmenen ainetta kärjessä.
48 Raunio H et al. Regulation of CYP3A genes in the human respiratory tract.
49 Seeman P et al. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.
50 Seppänen J, Juvonen R. Suippumyrkkyseitikkimyrkytys.
51 Tacke U, Ebert M. Hallucinogens and phencyclidine.
52 Van Larebeke NA et al. Unrecognized or potential risk factors for childhood cancer.
53 Venäläinen J. Characterization of Prolyl Oligopeptidase and its Inhibition.
54 Venäläinen JI et al. Synthesis and characterization of the novel fluorescent prolyl oligopeptidase inhibitor 4-fluoresceinthiocarbamoyl-6-aminocaproyl-L-prolyl-2(S)-(hydroxyacetyl)pyrrolidine.
55 Virtanen KA et al. Increased fat mass compensates for insulin resistance in abdominal obesity and type 2 diabetes. A positron-emitting tomography study.
56 Yavich L et al. Noradrenaline overflow in mouse dentate gyrus following locus coeruleus and natural stimulation: real-time monitoring by in vivo voltammetry.
57 Yavich L et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated alpha-synuclein.
58 Yavich L, Ylinen A. Spreading depression in the cortex differently modulates dopamine release in rat mesolimbic and nigrostriatal terminal fields.

Farmakologian ja toksikologian laitos Department of Pharmacology and Toxicology
Julkaisutietokanta 15.4.2008 Publications Data Base 15.4.2008